Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Sarcoma 3Ovarian Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Hodgkin Disease 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Seminoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Osteosarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Carboplatin 16Paclitaxel 9Cyclophosphamide 8liposomal doxorubicin 6Peripheral Blood Stem Cell Transplantation 6Topotecan 5Filgrastim 5pembrolizumab 4Docetaxel 4oregovomab 3veliparib 2sacituzumab govitecan 2epacadostat 2avelumab 2Thiotepa 2Taxes 2STA 9090 2Nivolumab 2Erlotinib Hydrochloride 2Drug Therapy 2Cisplatin 2Amifostine 2talazoparib 1ribociclib 1relacorilant 1ralimetinib 1poly ICLC 1phenoxodiol 1peginterferon alfa-2b 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Ovarian Epithelial × pegfilgrastim × Clear all
NCT00217529 2010-09-21

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡